Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

BACKGROUND: The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xinhua, Liu, Ping, Li, Donghe, Xia, Zhizhou, Wang, Peihong, Zhang, Xiuli, Liu, Mingzhu, Liao, Lujian, Jiao, Bo, Ren, Ruibao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302132/
https://www.ncbi.nlm.nih.gov/pubmed/32552902
http://dx.doi.org/10.1186/s13045-020-00912-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302132/
https://www.ncbi.nlm.nih.gov/pubmed/32552902
http://dx.doi.org/10.1186/s13045-020-00912-3

Ejemplares similares